TransMedics Group Inkomsten in het verleden
Verleden criteriumcontroles 2/6
TransMedics Group is de winst gegroeid met een gemiddeld jaarlijks percentage van 20.5%, terwijl de Medical Equipment industrie de winst jaarlijks groeide met 12.5%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 61.4% per jaar. Het rendement op eigen vermogen van TransMedics Group is 15.5%, en het heeft een nettomarge van 8.1%.
Belangrijke informatie
20.5%
Groei van de winst
35.0%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | 61.4% |
| Rendement op eigen vermogen | 15.5% |
| Nettomarge | 8.1% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
Nov 12What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash
Oct 30
TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
Oct 29TransMedics' Organ Care: Critical Innovation With Lofty Expectations
Oct 23TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
Oct 16Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Sep 18TransMedics: Take Profits While The Valuation Is Sky High
Sep 18TransMedics: Wide Moat Player At A Lower Valuation Than Peers
Sep 10TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce
Aug 28TransMedics: Heart And Lungs Will Drive The Next Leg Higher
Aug 19Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 27Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Apr 09Opbrengsten en kosten
Hoe TransMedics Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 401 | 33 | 154 | 50 |
| 30 Jun 24 | 359 | 3 | 142 | 47 |
| 31 Mar 24 | 297 | -10 | 129 | 42 |
| 31 Dec 23 | 242 | -25 | 118 | 36 |
| 30 Sep 23 | 192 | -36 | 107 | 31 |
| 30 Jun 23 | 151 | -18 | 93 | 27 |
| 31 Mar 23 | 119 | -28 | 81 | 25 |
| 31 Dec 22 | 93 | -36 | 70 | 27 |
| 30 Sep 22 | 72 | -42 | 60 | 27 |
| 30 Jun 22 | 51 | -48 | 54 | 26 |
| 31 Mar 22 | 39 | -47 | 45 | 25 |
| 31 Dec 21 | 30 | -44 | 38 | 22 |
| 30 Sep 21 | 28 | -38 | 32 | 21 |
| 30 Jun 21 | 30 | -30 | 28 | 20 |
| 31 Mar 21 | 25 | -28 | 24 | 17 |
| 31 Dec 20 | 26 | -29 | 24 | 19 |
| 30 Sep 20 | 24 | -32 | 24 | 21 |
| 30 Jun 20 | 24 | -35 | 25 | 21 |
| 31 Mar 20 | 26 | -36 | 26 | 22 |
| 28 Dec 19 | 24 | -34 | 24 | 20 |
| 28 Sep 19 | 21 | -32 | 22 | 17 |
| 29 Jun 19 | 18 | -29 | 18 | 15 |
| 30 Mar 19 | 15 | -26 | 15 | 14 |
| 29 Dec 18 | 13 | -24 | 12 | 14 |
| 29 Sep 18 | 12 | -21 | 10 | 14 |
| 30 Jun 18 | 9 | -20 | 9 | 14 |
| 31 Mar 18 | 8 | -20 | 8 | 14 |
| 30 Dec 17 | 8 | -21 | 8 | 15 |
| 31 Dec 16 | 6 | -24 | 8 | 16 |
Kwaliteitswinsten: TMDX heeft een hoog niveau van non-cash earnings.
Groeiende winstmarge: TMDX is in het verleden winstgevend geweest.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: TMDX is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 20.5% per jaar laten groeien.
Versnelling van de groei: TMDX is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.
Winst versus industrie: TMDX is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment -sector ( 11.7% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 15.5% ) van TMDX wordt als laag beschouwd.